Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry A Greenbaum

Showing results (51-60 of 170) with videos related to

Pageof 17
Sort By:
Pediatric Nephrology (Berlin, Germany)|December 9, 2020
Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumabKazuki Tanaka, Brigitte Adams, Alvaro Madrid Aris, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 26, 2015
The US pediatric nephrology workforce: a report commissioned by the American Academy of PediatricsWilliam A Primack, Kevin E Meyers, Suzanne J Kirkwood, et al.
Pediatric Transplantation|March 4, 2009
High prevalence of the metabolic syndrome and associated left ventricular hypertrophy in pediatric renal transplant recipientsAmy C Wilson, Larry A Greenbaum, Gina M Barletta, et al.
Clinical Transplantation|August 28, 2025
Effectiveness and Safety of Switching to Ravulizumab From Eculizumab in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome: A Global aHUS Registry AnalysisAnja Gaeckler, Imad Al-Dakkak, Nuria Saval, et al.
BMC Medical Informatics and Decision Making|June 1, 2019
Development of a novel mobile application to detect urine protein for nephrotic syndrome disease monitoringChia-Shi Wang, Richard Boyd, Russell Mitchell, et al.
Journal of Nephrology|July 2, 2021
Estimation of childhood nephrotic syndrome incidence: data from the atlanta metropolitan statistical area and meta-analysis of worldwide casesJackson Londeree, Courtney E McCracken, Larry A Greenbaum, et al.
Pediatric Transplantation|February 13, 2016
Deep procedural sedation by a sedationist team for outpatient pediatric renal biopsiesPradip P Kamat, Frank W Ayestaran, Scott E Gillespie, et al.
Pediatric Nephrology (Berlin, Germany)|October 31, 2003
Concurrent poststreptococcal glomerulonephritis and autoimmune hemolytic anemiaLarry A Greenbaum, Bryce A Kerlin, Scott Van Why, et al.
Kidney International Reports|July 13, 2023
Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic SyndromeDavid Kavanagh, Larry A Greenbaum, Arvind Bagga, et al.
BMC Nephrology|April 11, 2020
A dual efficacy-implementation trial of a novel mobile application for childhood nephrotic syndrome management: the UrApp for childhood nephrotic syndrome management pilot study protocol (UrApp pilot study)Chia-Shi Wang, Cam Escoffery, Rachel E Patzer, et al.
Pageof 17

Showing results (51-60 of 170) with videos related to

Sort By:
Pageof 17
Pediatric Nephrology (Berlin, Germany)|December 9, 2020
Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumabKazuki Tanaka, Brigitte Adams, Alvaro Madrid Aris, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 26, 2015
The US pediatric nephrology workforce: a report commissioned by the American Academy of PediatricsWilliam A Primack, Kevin E Meyers, Suzanne J Kirkwood, et al.
Pediatric Transplantation|March 4, 2009
High prevalence of the metabolic syndrome and associated left ventricular hypertrophy in pediatric renal transplant recipientsAmy C Wilson, Larry A Greenbaum, Gina M Barletta, et al.
Clinical Transplantation|August 28, 2025
Effectiveness and Safety of Switching to Ravulizumab From Eculizumab in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome: A Global aHUS Registry AnalysisAnja Gaeckler, Imad Al-Dakkak, Nuria Saval, et al.
BMC Medical Informatics and Decision Making|June 1, 2019
Development of a novel mobile application to detect urine protein for nephrotic syndrome disease monitoringChia-Shi Wang, Richard Boyd, Russell Mitchell, et al.
Journal of Nephrology|July 2, 2021
Estimation of childhood nephrotic syndrome incidence: data from the atlanta metropolitan statistical area and meta-analysis of worldwide casesJackson Londeree, Courtney E McCracken, Larry A Greenbaum, et al.
Pediatric Transplantation|February 13, 2016
Deep procedural sedation by a sedationist team for outpatient pediatric renal biopsiesPradip P Kamat, Frank W Ayestaran, Scott E Gillespie, et al.
Pediatric Nephrology (Berlin, Germany)|October 31, 2003
Concurrent poststreptococcal glomerulonephritis and autoimmune hemolytic anemiaLarry A Greenbaum, Bryce A Kerlin, Scott Van Why, et al.
Kidney International Reports|July 13, 2023
Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic SyndromeDavid Kavanagh, Larry A Greenbaum, Arvind Bagga, et al.
BMC Nephrology|April 11, 2020
A dual efficacy-implementation trial of a novel mobile application for childhood nephrotic syndrome management: the UrApp for childhood nephrotic syndrome management pilot study protocol (UrApp pilot study)Chia-Shi Wang, Cam Escoffery, Rachel E Patzer, et al.
Pageof 17